Bortezomib API Market Synopsis

Bortezomib API Market Size Was Valued at USD 23.53 Million in 2022, and is Projected to Reach USD 33.46 Million by 2030, Growing at a CAGR of 4.5% From 2023-2030.

Bortezomib is a pharmaceutical active ingredient, classified as a proteasome inhibitor used in cancer treatment, particularly for multiple myeloma and mantle cell lymphoma. It functions by disrupting the activity of proteasomes, cellular complexes crucial for protein degradation. By inhibiting this process, bortezomib promotes cell death in cancerous cells. Its mechanism of action makes it an essential component of various chemotherapy regimens.

• Bortezomib plays a crucial role in the formulation of various branded and generic medications targeting these diseases.The market for bortezomib API has witnessed significant growth owing to the rising incidence of multiple myeloma and mantle cell lymphoma worldwide. The increasing popularity of these malignancies, with advancements in cancer diagnosis and treatment, has driven the demand for bortezomib-based therapies.
• Demand for the bortezomib API market is expanding due to geriatric population, which is more susceptible to hematologic malignancies, and the introduction of innovative treatment regimens incorporating bortezomib in combination therapies. The market for bortezomib API is distributed across regions with a high prevalence of multiple myeloma and mantle cell lymphoma, such as North America, Europe, and the Asia-Pacific.
• These regions also boast well-established healthcare infrastructure and robust pharmaceutical industries, facilitating the widespread adoption of bortezomib-based therapies.Furthermore, ongoing research and development initiatives exploring new indications for bortezomib and enhancing its therapeutic efficacy are expected to fuel market expansion in the coming years.

Bortezomib API Market Trend Analysis

Increasing Incidence of Cancer

• Bortezomib is a crucial component in the treatment of various cancers, including multiple myeloma and mantle cell lymphoma. As cancer rates continue to rise globally, particularly in aging populations and regions with lifestyle-related risk factors, the demand for effective cancer therapies like bortezomib has intensified.
• The drug's mechanism of action, targeting cancer cells specifically, made it a cornerstone in modern oncology. The ongoing research and clinical trials exploring its efficacy in treating other cancer types further propel market growth. Pharmaceutical companies are investing heavily in developing and manufacturing bortezomib API to meet the rising demand from healthcare providers and patients.
• Advancements in biotechnology and personalized medicine have opened new avenues for targeted therapies, increasing the adoption of bortezomib in precision oncology. The predominant trend of rising cancer incidence ensures a promising position for the bortezomib API market.

Growing Depend on Cost-Effective Treatments

• The Bortezomib API market is witnessing a significant surge, primarily propelled by the growing reliance on cost-effective treatments. This trend signifies a pivotal opportunity for stakeholders within the pharmaceutical industry. Bortezomib, a vital active pharmaceutical ingredient (API) used in the treatment of multiple myeloma and mantle cell lymphoma, is experiencing heightened demand due to its efficacy and affordability.
• Healthcare providers and patients alike are increasingly prioritizing treatments offer substantial therapeutic benefits without imposing a heavy financial burden. The accessibility and affordability of Bortezomib API have become key determinants in treatment decisions. This shift focus towards cost-effective solutions enhances patient access to essential medications in raises market expansion and innovation within the pharmaceutical sector.
• The importance on cost-effectiveness in healthcare systems worldwide promote the demand for Bortezomib API. Market players are presented with a prime opportunity to capitalize on growing need by developing competitive pricing strategies and expanding their market reach.

Bortezomib API Market Segment Analysis:

Bortezomib API Market Segmented on the basis of Product Type, End-User, and Distribution Channel.

By Type, Purity segment is expected to dominate the market during the forecast period

• The Purity segment, Bortezomib, a proteasome inhibitor utilized in the treatment of multiple myeloma and mantle cell lymphoma, demands stringent quality standards, with purity being a supreme concern.
• Purity directly correlates with the effectiveness and safety of the final drug formulation. Consequently, pharmaceutical manufacturers prioritize sourcing Bortezomib APIs with the highest purity levels to ensure optimal therapeutic outcomes and minimize adverse effects. This emphasis on purity stems from regulatory requirements and the uncompromising commitment to patient welfare within the pharmaceutical industry.
• The advancements in manufacturing technologies and processes contribute to the escalation of purity levels achievable in Bortezomib APIs, and dominance of the Purity segment dedication to delivering superior quality medications.

By End-User, Hospitals segment held the largest share of xx% in 2022

• Hospitals serve as crucial hubs for administering medications like Bortezomib, especially in the context of diseases like multiple myeloma. The specialized nature of Bortezomib treatment and its requirement for careful monitoring and management, hospitals are well-equipped to handle its distribution and administration. Hospitals have established relationships with pharmaceutical suppliers and access to resources for procuring APIs efficiently.
• Hospitals are central to the healthcare ecosystem, serving as primary points of contact for patients seeking medical care. This positions them as key drivers of demand for Bortezomib API, as they play a pivotal role in diagnosing, treating, and managing conditions that necessitate Bortezomib therapy. Their ability to provide comprehensive care, including chemotherapy and supportive services, further emphasises their prominence in the Bortezomib API market.
• Hospitals have specialized oncology departments and experienced medical professionals are adept at handling complex treatments like Bortezomib therapy. This expertise and infrastructure enable hospitals to dominate the Bortezomib API market, as they offer a centralized and reliable source of treatment for patients requiring this medication

Bortezomib API Market Regional Insights:

Asia Pacific is expected to dominate the Market over the Forecast period

• Asia Pacific boasts a robust pharmaceutical manufacturing industry, particularly in countries like India and China, known for their cost-effective production capabilities and skilled labor force. This region has witnessed significant investments in infrastructure and technology, enabling efficient API production.
• The government policies and initiatives aimed at promoting the pharmaceutical sector have raised growth and innovation in API manufacturing. Tax incentives, streamlined regulatory processes, and supportive policies attract both domestic and international pharmaceutical companies to invest in the region.
• The growing prevalence of diseases such as multiple myeloma, Bortezomib is a key treatment, drives the demand for APIs in the Asia Pacific. The region's large and aging population, coupled with increasing healthcare expenditure, further accelerates this demand.
• Furthermore, strategic collaborations and partnerships between regional and global pharmaceutical players strengthen the supply chain and distribution networks in the Asia Pacific market. These collaborations facilitate technology transfer, knowledge exchange, and capacity building, enhancing the overall competitiveness of the region in the global API market.
• The growing pharmaceutical industry, supportive regulatory environment, rising disease problem, and collaborative ecosystem, dominate the Bortezomib API market over the forecast period in Asia Pacific Region.

Bortezomib API Market Top Key Players:

• Icrom (Italy)
• Tapi Teva (Israel)
• Farmhispania Group (Spain)
• Coresyn (Brazil)
• Scion Pharm Taiwan (Taiwan)
• Gland Chemicals (India)
• Shilpa Medicare Limited (India)
• Dr. Reddy's Laboratories (India)
• Qilu Pharmaceutial (China)
• Chengdu Aslee Biopharmaceuticals (China)
• Chem-Stone (Guangzhou) (China)
• Hubei Honch Pharmaceutical (China)
• Vinkem Labs (South Africa), and Other Major Players.

Key Industry Developments in the Bortezomib API Market:

• In November 2022, Gland Pharma Limited announced the initiation of a Put Option Agreement by its subsidiary, Gland Pharma International PTE. Ltd, Singapore, to acquire 100% equity stake in Cenexi Group for a value not exceeding Euro 120 million (approx. Rs101.36 crore). Specializing in CDMO of pharmaceuticals, Cenexi Group operates four manufacturing sites in Europe, with expertise in sterile liquid and lyophilized fill finished drugs. Gland Pharma aims to expand its European CDMO offerings through this strategic acquisition.

1. INTRODUCTION
   1. RESEARCH OBJECTIVES
   2. RESEARCH METHODOLOGY
   3. RESEARCH PROCESS
   4. SCOPE AND COVERAGE
      1. Market Definition
      2. Key Questions Answered
   5. MARKET SEGMENTATION
2. EXECUTIVE SUMMARY
3. MARKET OVERVIEW
4. GROWTH OPPORTUNITIES BY SEGMENT
5. MARKET LANDSCAPE
   1. PORTER’S FIVE FORCES ANALYSIS
      1. Bargaining Power Of Supplier
      2. Threat Of New Entrants
      3. Threat Of Substitutes
      4. Competitive Rivalry
      5. Bargaining Power Among Buyers
   2. INDUSTRY VALUE CHAIN ANALYSIS
   3. MARKET DYNAMICS
      1. Drivers
      2. Restraints
      3. Opportunities
      4. Challenges
   4. MARKET TREND ANALYSIS
   5. REGULATORY LANDSCAPE
   6. PESTLE ANALYSIS
   7. PRICE TREND ANALYSIS
   8. PATENT ANALYSIS
   9. TECHNOLOGY EVALUATION
   10. MARKET IMPACT OF THE RUSSIA-UKRAINE WAR
       1. Geopolitical Market Disruptions
       2. Supply Chain Disruptions
       3. Instability in Emerging Markets
   11. ECOSYSTEM
6. BORTEZOMIB API MARKET BY PRODUCT TYPE (2017-2030)
   1. BORTEZOMIB API MARKET SNAPSHOT AND GROWTH ENGINE
   2. MARKET OVERVIEW
   3. PURITY
      1. Introduction And Market Overview
      2. Historic And Forecasted Market Size in Value (2017 – 2030F)
      3. Historic And Forecasted Market Size in Volume (2017 – 2030F)
      4. Key Market Trends, Growth Factors And Opportunities
      5. Geographic Segmentation Analysis
   4. FORM
7. BORTEZOMIB API MARKET BY END-USER (2017-2030)
   1. BORTEZOMIB API MARKET SNAPSHOT AND GROWTH ENGINE
   2. MARKET OVERVIEW
   3. HOSPITALS
      1. Introduction And Market Overview
      2. Historic And Forecasted Market Size in Value (2017 – 2030F)
      3. Historic And Forecasted Market Size in Volume (2017 – 2030F)
      4. Key Market Trends, Growth Factors And Opportunities
      5. Geographic Segmentation Analysis
   4. SPECIALTY CLINICS
   5. RESEARCH INSTITUTES
8. BORTEZOMIB API MARKET BY DISTRIBUTION CHANNEL (2017-2030)
   1. BORTEZOMIB API MARKET SNAPSHOT AND GROWTH ENGINE
   2. MARKET OVERVIEW
   3. DIRECT SALES
      1. Introduction And Market Overview
      2. Historic And Forecasted Market Size in Value (2017 – 2030F)
      3. Historic And Forecasted Market Size in Volume (2017 – 2030F)
      4. Key Market Trends, Growth Factors And Opportunities
      5. Geographic Segmentation Analysis
   4. DISTRIBUTOR
9. COMPANY PROFILES AND COMPETITIVE ANALYSIS
   1. COMPETITIVE LANDSCAPE
      1. Competitive Positioning
      2. Bortezomib API Market Share By Manufacturer (2022)
      3. Industry BCG Matrix
      4. Heat Map Analysis
      5. Mergers & Acquisitions
   2. ICROM (ITALY)
      1. Company Overview
      2. Key Executives
      3. Company Snapshot
      4. Role of the Company in the Market
      5. Sustainability and Social Responsibility
      6. Operating Business Segments
      7. Product Portfolio
      8. Business Performance (Production Volume, Sales Volume, Sales Margin, Production Capacity, Capacity Utilization Rate)
      9. Key Strategic Moves And Recent Developments
      10. SWOT Analysis
   3. TAPI TEVA (ISRAEL)
   4. FARMHISPANIA GROUP (SPAIN)
   5. CORESYN (BRAZIL)
   6. SCION PHARM TAIWAN (TAIWAN)
   7. GLAND CHEMICALS (INDIA)
   8. SHILPA MEDICARE LIMITED (INDIA)
   9. DR. REDDY'S LABORATORIES (INDIA)
   10. QILU PHARMACEUTIAL (CHINA)
   11. CHENGDU ASLEE BIOPHARMACEUTICALS (CHINA)
   12. CHEM-STONE (GUANGZHOU) (CHINA)
   13. HUBEI HONCH PHARMACEUTICAL (CHINA)
   14. VINKEM LABS (SOUTH AFRICA)
10. GLOBAL BORTEZOMIB API MARKET BY REGION
    1. OVERVIEW
    2. NORTH AMERICA
       1. Key Market Trends, Growth Factors And Opportunities
       2. Key Manufacturers
       3. Historic And Forecasted Market Size By Product Type
       4. Historic And Forecasted Market Size By End-User
       5. Historic And Forecasted Market Size By Distribution Channel
       6. Historic And Forecasted Market Size By Country
          1. USA
          2. Canada
          3. Mexico
    3. EASTERN EUROPE
       1. Key Market Trends, Growth Factors And Opportunities
       2. Key Manufacturers
       3. Historic And Forecasted Market Size By Segments
       4. Historic And Forecasted Market Size By Country
          1. Russia
          2. Bulgaria
          3. The Czech Republic
          4. Hungary
          5. Poland
          6. Romania
          7. Rest Of Eastern Europe
    4. WESTERN EUROPE
       1. Key Market Trends, Growth Factors And Opportunities
       2. Key Manufacturers
       3. Historic And Forecasted Market Size By Segments
       4. Historic And Forecasted Market Size By Country
          1. Germany
          2. United Kingdom
          3. France
          4. The Netherlands
          5. Italy
          6. Spain
          7. Rest Of Western Europe
    5. ASIA PACIFIC
       1. Key Market Trends, Growth Factors And Opportunities
       2. Key Manufacturers
       3. Historic And Forecasted Market Size By Segments
       4. Historic And Forecasted Market Size By Country
          1. China
          2. India
          3. Japan
          4. South Korea
          5. Malaysia
          6. Thailand
          7. Vietnam
          8. The Philippines
          9. Australia
          10. New-Zealand
          11. Rest Of APAC
    6. MIDDLE EAST & AFRICA
       1. Key Market Trends, Growth Factors And Opportunities
       2. Key Manufacturers
       3. Historic And Forecasted Market Size By Segments
       4. Historic And Forecasted Market Size By Country
          1. Turkey
          2. Bahrain
          3. Kuwait
          4. Saudi Arabia
          5. Qatar
          6. UAE
          7. Israel
          8. South Africa
    7. SOUTH AMERICA
       1. Key Market Trends, Growth Factors And Opportunities
       2. Key Manufacturers
       3. Historic And Forecasted Market Size By Segments
       4. Historic And Forecasted Market Size By Country
          1. Brazil
          2. Argentina
          3. Rest of South America
11. INVESTMENT ANALYSIS
12. ANALYST VIEWPOINT AND CONCLUSION
    1. Recommendations and Concluding Analysis
    2. Potential Market Strategies

LIST OF TABLES

TABLE 001. EXECUTIVE SUMMARY
TABLE 002. BORTEZOMIB API MARKET BARGAINING POWER OF SUPPLIERS
TABLE 003. BORTEZOMIB API MARKET BARGAINING POWER OF CUSTOMERS
TABLE 004. BORTEZOMIB API MARKET COMPETITIVE RIVALRY
TABLE 005. BORTEZOMIB API MARKET THREAT OF NEW ENTRANTS
TABLE 006. BORTEZOMIB API MARKET THREAT OF SUBSTITUTES
TABLE 007. BORTEZOMIB API MARKET BY TYPE
TABLE 008. PURITY ? 98 % MARKET OVERVIEW (2016-2028)
TABLE 009. PURITY ? 99 % MARKET OVERVIEW (2016-2028)
TABLE 010. BORTEZOMIB API MARKET BY APPLICATION
TABLE 011. INJECTION MARKET OVERVIEW (2016-2028)
TABLE 012. OTHERS MARKET OVERVIEW (2016-2028)
TABLE 013. NORTH AMERICA BORTEZOMIB API MARKET, BY TYPE (2016-2028)
TABLE 014. NORTH AMERICA BORTEZOMIB API MARKET, BY APPLICATION (2016-2028)
TABLE 015. N BORTEZOMIB API MARKET, BY COUNTRY (2016-2028)
TABLE 016. EUROPE BORTEZOMIB API MARKET, BY TYPE (2016-2028)
TABLE 017. EUROPE BORTEZOMIB API MARKET, BY APPLICATION (2016-2028)
TABLE 018. BORTEZOMIB API MARKET, BY COUNTRY (2016-2028)
TABLE 019. ASIA PACIFIC BORTEZOMIB API MARKET, BY TYPE (2016-2028)
TABLE 020. ASIA PACIFIC BORTEZOMIB API MARKET, BY APPLICATION (2016-2028)
TABLE 021. BORTEZOMIB API MARKET, BY COUNTRY (2016-2028)
TABLE 022. MIDDLE EAST & AFRICA BORTEZOMIB API MARKET, BY TYPE (2016-2028)
TABLE 023. MIDDLE EAST & AFRICA BORTEZOMIB API MARKET, BY APPLICATION (2016-2028)
TABLE 024. BORTEZOMIB API MARKET, BY COUNTRY (2016-2028)
TABLE 025. SOUTH AMERICA BORTEZOMIB API MARKET, BY TYPE (2016-2028)
TABLE 026. SOUTH AMERICA BORTEZOMIB API MARKET, BY APPLICATION (2016-2028)
TABLE 027. BORTEZOMIB API MARKET, BY COUNTRY (2016-2028)
TABLE 028. SCION PHARM TAIWAN: SNAPSHOT
TABLE 029. SCION PHARM TAIWAN: BUSINESS PERFORMANCE
TABLE 030. SCION PHARM TAIWAN: PRODUCT PORTFOLIO
TABLE 031. SCION PHARM TAIWAN: KEY STRATEGIC MOVES AND DEVELOPMENTS
TABLE 031. VINKEM LABS: SNAPSHOT
TABLE 032. VINKEM LABS: BUSINESS PERFORMANCE
TABLE 033. VINKEM LABS: PRODUCT PORTFOLIO
TABLE 034. VINKEM LABS: KEY STRATEGIC MOVES AND DEVELOPMENTS
TABLE 034. SHILPA MEDICARE LIMITED: SNAPSHOT
TABLE 035. SHILPA MEDICARE LIMITED: BUSINESS PERFORMANCE
TABLE 036. SHILPA MEDICARE LIMITED: PRODUCT PORTFOLIO
TABLE 037. SHILPA MEDICARE LIMITED: KEY STRATEGIC MOVES AND DEVELOPMENTS
TABLE 037. FARMHISPANIA GROUP: SNAPSHOT
TABLE 038. FARMHISPANIA GROUP: BUSINESS PERFORMANCE
TABLE 039. FARMHISPANIA GROUP: PRODUCT PORTFOLIO
TABLE 040. FARMHISPANIA GROUP: KEY STRATEGIC MOVES AND DEVELOPMENTS
TABLE 040. ICROM: SNAPSHOT
TABLE 041. ICROM: BUSINESS PERFORMANCE
TABLE 042. ICROM: PRODUCT PORTFOLIO
TABLE 043. ICROM: KEY STRATEGIC MOVES AND DEVELOPMENTS
TABLE 043. TAPI TEVA: SNAPSHOT
TABLE 044. TAPI TEVA: BUSINESS PERFORMANCE
TABLE 045. TAPI TEVA: PRODUCT PORTFOLIO
TABLE 046. TAPI TEVA: KEY STRATEGIC MOVES AND DEVELOPMENTS
TABLE 046. CHEM-STONE(GUANGZHOU): SNAPSHOT
TABLE 047. CHEM-STONE(GUANGZHOU): BUSINESS PERFORMANCE
TABLE 048. CHEM-STONE(GUANGZHOU): PRODUCT PORTFOLIO
TABLE 049. CHEM-STONE(GUANGZHOU): KEY STRATEGIC MOVES AND DEVELOPMENTS
TABLE 049. GLAND CHEMICALS: SNAPSHOT
TABLE 050. GLAND CHEMICALS: BUSINESS PERFORMANCE
TABLE 051. GLAND CHEMICALS: PRODUCT PORTFOLIO
TABLE 052. GLAND CHEMICALS: KEY STRATEGIC MOVES AND DEVELOPMENTS
TABLE 052. DR. REDDY'S LABORATORIES: SNAPSHOT
TABLE 053. DR. REDDY'S LABORATORIES: BUSINESS PERFORMANCE
TABLE 054. DR. REDDY'S LABORATORIES: PRODUCT PORTFOLIO
TABLE 055. DR. REDDY'S LABORATORIES: KEY STRATEGIC MOVES AND DEVELOPMENTS
TABLE 055. QILU PHARMACEUTIAL: SNAPSHOT
TABLE 056. QILU PHARMACEUTIAL: BUSINESS PERFORMANCE
TABLE 057. QILU PHARMACEUTIAL: PRODUCT PORTFOLIO
TABLE 058. QILU PHARMACEUTIAL: KEY STRATEGIC MOVES AND DEVELOPMENTS
TABLE 058. CHENGDU ASLEE BIOPHARMACEUTICALS: SNAPSHOT
TABLE 059. CHENGDU ASLEE BIOPHARMACEUTICALS: BUSINESS PERFORMANCE
TABLE 060. CHENGDU ASLEE BIOPHARMACEUTICALS: PRODUCT PORTFOLIO
TABLE 061. CHENGDU ASLEE BIOPHARMACEUTICALS: KEY STRATEGIC MOVES AND DEVELOPMENTS
TABLE 061. CORESYN: SNAPSHOT
TABLE 062. CORESYN: BUSINESS PERFORMANCE
TABLE 063. CORESYN: PRODUCT PORTFOLIO
TABLE 064. CORESYN: KEY STRATEGIC MOVES AND DEVELOPMENTS
TABLE 064. HUBEI HONCH PHARMACEUTICAL: SNAPSHOT
TABLE 065. HUBEI HONCH PHARMACEUTICAL: BUSINESS PERFORMANCE
TABLE 066. HUBEI HONCH PHARMACEUTICAL: PRODUCT PORTFOLIO
TABLE 067. HUBEI HONCH PHARMACEUTICAL: KEY STRATEGIC MOVES AND DEVELOPMENTS

LIST OF FIGURES

FIGURE 001. YEARS CONSIDERED FOR ANALYSIS
FIGURE 002. SCOPE OF THE STUDY
FIGURE 003. BORTEZOMIB API MARKET OVERVIEW BY REGIONS
FIGURE 004. PORTER'S FIVE FORCES ANALYSIS
FIGURE 005. BARGAINING POWER OF SUPPLIERS
FIGURE 006. COMPETITIVE RIVALRYFIGURE 007. THREAT OF NEW ENTRANTS
FIGURE 008. THREAT OF SUBSTITUTES
FIGURE 009. VALUE CHAIN ANALYSIS
FIGURE 010. PESTLE ANALYSIS
FIGURE 011. BORTEZOMIB API MARKET OVERVIEW BY TYPE
FIGURE 012. PURITY ? 98 % MARKET OVERVIEW (2016-2028)
FIGURE 013. PURITY ? 99 % MARKET OVERVIEW (2016-2028)
FIGURE 014. BORTEZOMIB API MARKET OVERVIEW BY APPLICATION
FIGURE 015. INJECTION MARKET OVERVIEW (2016-2028)
FIGURE 016. OTHERS MARKET OVERVIEW (2016-2028)
FIGURE 017. NORTH AMERICA BORTEZOMIB API MARKET OVERVIEW BY COUNTRY (2016-2028)
FIGURE 018. EUROPE BORTEZOMIB API MARKET OVERVIEW BY COUNTRY (2016-2028)
FIGURE 019. ASIA PACIFIC BORTEZOMIB API MARKET OVERVIEW BY COUNTRY (2016-2028)
FIGURE 020. MIDDLE EAST & AFRICA BORTEZOMIB API MARKET OVERVIEW BY COUNTRY (2016-2028)
FIGURE 021. SOUTH AMERICA BORTEZOMIB API MARKET OVERVIEW BY COUNTRY (2016-2028)